Swedish Orphan Plunges After Talks End on Potential Takeover

Swedish Orphan Biovitrum AB fell as much as 19 percent after the maker of treatments for rare diseases said it ended talks on a possible takeover offer.

The drugmaker, better known as Sobi, has held talks with potential buyers since last year, Bloomberg reported in April, citing people familiar with the matter. Pfizer Inc., which has a partnership with the Swedish company, and Biogen Inc., which also works with Sobi, were among companies that may have been interested, the people said.